Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treate
- PDF / 404,691 Bytes
- 7 Pages / 595.276 x 841.89 pts (A4) Page_size
- 3 Downloads / 127 Views
40(3):563-569,2020
563
Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics* Xue-lin CHAO1†, Shu-zhen JIANG2†, Jian-wen XIONG3, Jin-qiong ZHAN2, Bo WEI2, 3, Chun-nuan CHEN4#, Yuan-jian YANG2, 3# 1 Department of Psychosomatic Medicine, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China 2 Biological Psychiatry Laboratory, Jiangxi Mental Hospital/Affiliated Mental Hospital of Nanchang University, Nanchang 330029, China 3 Department of Psychiatry, Jiangxi Mental Hospital/Affiliated Mental Hospital of Nanchang University, Nanchang 330029, China 4 Department of Neurology, The Second Clinical Medical College, The Second Affiliated Hospital, Fujian Medical University, Quanzhou 362000, China Huazhong University of Science and Technology 2020
Summary: Accumulating evidence suggests that a disruption of early brain development, in which insulin-like growth factor-2 (IGF-2) has a crucial role, may underlie the pathophysiology of schizophrenia. Our previous study has shown that decreased serum IGF-2 was correlated with the severity of psychopathology in patients with schizophrenia. Here we conducted a prospective observation trial to investigate the effects of atypical antipsychotics on serum IGF-2 level and its relationship with clinical improvements in schizophrenia patients. Thirty-one schizophrenia patients with acute exacerbation and 30 healthy individuals were recruited in this study. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) and serum IGF-2 levels were determined using ELISA. We found that schizophrenia patients with acute exacerbation had lower serum IGF-2 levels than control individuals at baseline (P
Data Loading...
